Roth Capital Upgraded Peregrine Pharma Following Internal Review of Trial

Roth Capital upgraded Peregrine Pharmaceuticals Inc. PPHM following news of an update from its internal review of discrepancies from its Phase II randomized, double-blind placebo-controlled trial of bavituximab in second-line non-small cell lung cancer (NSCLC) in 121 patients. The firm raised its rating from Neutral to Buy and boosted its price target from $1.25 to $2.70.